Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.1K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-I: Introduction01:29

Asthma-I: Introduction

3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Science, medicine and ethics during COVID-19 pandemic.

Acta paediatrica (Oslo, Norway : 1992)·2021
Same author

Return to School for Children With Tracheostomy or Requiring Noninvasive Ventilation Lessons From the First Lockdown in the United Kingdom.

Chest·2021
Same author

Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.

Allergy·2021
Same author

E-Cigarettes as a Growing Threat for Children and Adolescents: Position Statement From the European Academy of Paediatrics.

Frontiers in pediatrics·2021
Same author

COVID-19 and delivery of difficult asthma services.

Archives of disease in childhood·2021
Same author

Electronic reminders and rewards to improve adherence to inhaled asthma treatment in adolescents: a non-randomised feasibility study in tertiary care.

BMJ open·2021
Same journal

Impact of cognitive impairment and depression on asthma in older patients.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Refractory Atopic Dermatitis Unmasking Mycosis Fungoides During Targeted Therapy.

The journal of allergy and clinical immunology. In practice·2026
Same journal

ASTHMA CONTROL BEFORE AND AFTER CHANGING GAS STOVES TO ELECTRIC STOVES.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Multiplex Cytokine LTT Reveals Strong T Cell Responses to Multiple Drugs in NIDHR-Associated Multiple Drug Hypersensitivity.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Allergic Fungal Rhinosinusitis: Distinct Clinical Features, Diagnostic Challenges, and Evolving Therapeutic Strategies.

The journal of allergy and clinical immunology. In practice·2026
Same journal

Effectiveness of treatment with tezepelumab in patients with severe asthma, smoking asthmatics and patients with severe Asthma and COPD: A real-world cohort study.

The journal of allergy and clinical immunology. In practice·2026
See all related articles

Related Experiment Video

Updated: Jan 2, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.3K

Eosinophilic Asthma.

Ryan K Nelson1, Andrew Bush2, Jeffrey Stokes3

  • 1Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of California San Diego, La Jolla, Calif.

The Journal of Allergy and Clinical Immunology. in Practice
|December 2, 2019
PubMed
Summary
This summary is machine-generated.

Asthma endotypes are complex and evolving, with no universal definition. This study outlines an approach to identify specific asthma phenotypes, including TH2-high and aspirin-exacerbated respiratory disease, using biomarkers for targeted biologic therapies.

Keywords:
Aspirin-exacerbated respiratory diseaseAsthmaEndotypesEosinophils

More Related Videos

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

28.5K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.1K

Related Experiment Videos

Last Updated: Jan 2, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
03:23

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis

Published on: May 10, 2024

1.3K
Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

28.5K
Murine Model of Allergen Induced Asthma
08:05

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

41.1K

Area of Science:

  • Pulmonology and Immunology
  • Biomarker Discovery
  • Personalized Medicine

Background:

  • Asthma endotypes are not universally defined, leading to challenges in classification.
  • The TH2-high endotype, characterized by eosinophilic airway inflammation, can be allergic or nonallergic.
  • Distinct asthma phenotypes, including aspirin-exacerbated respiratory disease, require specific diagnostic criteria.

Purpose of the Study:

  • To outline an approach for identifying distinct asthma endotypes and phenotypes.
  • To facilitate the selection of targeted therapeutic strategies, particularly biologic agents.
  • To address the evolving landscape of asthma classification and treatment.

Main Methods:

  • Utilizing unbiased clustering analyses to identify pediatric and adult asthma phenotypes.
  • Employing biomarkers for the identification of specific endotype groups.
  • Reviewing current approaches for classifying respiratory diseases.

Main Results:

  • Identification of TH2-high inflammation phenotypes in both pediatric and adult asthma cohorts.
  • Recognition of aspirin-exacerbated respiratory disease as a distinct phenotype.
  • Development of a biomarker-driven strategy for patient stratification.

Conclusions:

  • A biomarker-based approach can effectively identify distinct asthma endotypes and phenotypes.
  • Targeted therapies, especially biologics, can be guided by precise endotype identification.
  • Further research is needed to refine universally accepted criteria for asthma endotyping.